Training program in the biology and translational research on Alzheimer's diseaseand related dementias

阿尔茨海默病和相关痴呆症的生物学和转化研究培训计划

基本信息

批准号：
10628893
负责人：
Stephanie M Cologna
金额：
$ 33.06万
依托单位：
UNIVERSITY OF ILLINOIS AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-15 至 2028-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10628893
关键词：
Alzheimer&apos s Disease Biology Dementia Training Programs Translational Research

项目摘要

Project Summary This T32 renewal application seeks support for the multidisciplinary education of trainees in Alzheimer’s disease and Related Dementia (ADRD). The goal of this program is to train the next generation of creative and meritorious ADRD researchers at the predoctoral level. We acknowledge that the development of future therapy for dementia will require strong training in multiple disciplines, such as, the molecular biology of dementia, drug discovery and development, clinical studies and the analysis of large data sets. We will answer the imperative need for scientists who can synthesize across disciplines. Our Training Program comprises of four discplines/themes: (1) biological mechanisms (2) drug discovery and development (3) clinical ADRD (4) computational science. Each student gets trained in at least two of the four disciplines, utilizing a multidisciplinary approach for tackling scientific questions in ADRD. Attentive to the latest recommendation of the NIA and Alzheimer’s Association guidelines, there will be special emphasize on the analysis of lifestyle, environmental factors and preventative approaches for ADRD. The mentor/preceptor team has outstanding expertise to establish this innovative, interdisciplinary training program, to integrate otherwise disparate centers of excellence at UIC and Rush, leveraged by industry collaborations. Preceptor expertise is diverse; from molecular mechanisms of dementia, vascular biology, diabetes and inflammation, neuronal and neural imaging to clinical diagnosis of human ADRD patients and large scale data analysis. Expertise is from 12 departments and 6 clinical and translational entities. We will train ADRD researchers with diverse backgrounds and cross- disciplinary skills, including neuroscientists, but also computational biologists, chemists, and engineers interested in translational ADRD research. To facilitate interdisciplinary training, trainees will have two preceptors from different disciplines. We will build individual development plans (IDPs) for each trainee and offer multidisciplinary coursework from ADRD-TP faculty and pharma scientists. Importantly, trainees can perform translational research at any of the affiliated clinical and translational entities. Trainees will be encouraged to collaborate with large community-based NIH-supported studies (ROS/MAP) or NIA’s large-scale collaborative consortia (AMP-AD, M2OVE-AD, ADNI, ACTC), and with our pharma partners, Eli Lilly, Abbott and Baxter. Trainees are encouraged to participate in workshops geared towards -omics and drug discovery and the CIM/MATTER entrepreneurial program that aids commercialization of scientific innovation. We seek to support 6 predoctoral trainees. The success of this program in the last five years is reflected by our alumni who have moved on to successful careers in academia and pharma. The ADRD-TP’s vitality is reflected by the numbers of highly qualified applicants and state-of-the-art scientific endevours and publications. We expect the next five year to surpass this success. In summary, the ADRD-TP will provide a rigorous, inspiring and nurturing environment to ensure training of the highest level of scientists needed to unravel dementia.

项目摘要该T32更新申请寻求支持阿尔茨海默氏病学员的多学科教育和相关的痴呆症（ADRD）。优点研究人员在左右。对于痴呆症，需要在多个学科中进行强有力的训练，例如痴呆症的分子生物学，药物。发现与发展，临床研究以及大型数据集的分析。需要跨学科合成的科学家。截面/主题：（1）生物学机制（2）药物发现与发育（3）临床ADRD（4）计算科学。在ADRD中解决科学问题的方法。阿尔茨海默氏症协会指南，将特别强调生活方式的分析 ADRD的因素和预防方法。建立这个创新的跨学科培训计划，以整合原本的卓越性能在UIC和RUSH，由行业合作所利用。痴呆，血管生物学，糖尿病和炎症，神经元和神经成像的机制人类ADRD患者的诊断和大规模数据分析。临床和翻译实体。纪律技能，包括神经科学家，以及计算生物学家，化学家和工程师对转化的ADRD研究感兴趣。来自不同的学科。 ADRD-TP教师和制药科学家的多学科课程。鼓励临床和转化的转化研究与基于基于社区的大型NIH支持的研究（ROS/MAP）或NIA的大规模合作财团（AMP-AD，M2OVE-AD，ADNI，ACTC），以及我们的制药合作伙伴Eli Lilly，Abbott和Baxter。鼓励受训人员参加涉足 - 派和毒品发现的研讨会和你 CIM/物质企业家计划有助于我们寻求支持科学创新。 6个授权的学员。转向学术界和制药的成功职业。在高素质的申请人和最先进的科学界面和出版物中。 y在总结中超越了这一点，ADRD-TP将提供严格的，鼓舞人心的确保培训最高水平的科学家所需的环境。